GB9200420D0
(en)
|
1992-01-09 |
1992-02-26 |
James Black Foundation The Lim |
Amino acid derivatives
|
ATE152095T1
(de)
|
1992-02-20 |
1997-05-15 |
Black James Foundation |
Bicyclo(2.2.2.>oktan derivate als cholestocystokinin harnstoffe
|
JPH08508743A
(ja)
|
1993-04-15 |
1996-09-17 |
グラクソ、ウェルカム、インコーポレーテッド |
Cckおよび/またはガストリン拮抗作用を有する1,5−ベンゾジアゼピン誘導体
|
US6334997B1
(en)
|
1994-03-25 |
2002-01-01 |
Isotechnika, Inc. |
Method of using deuterated calcium channel blockers
|
ATE372966T1
(de)
|
1994-03-25 |
2007-09-15 |
Isotechnika Inc |
Verbesserung der effektivität von arzneimitteln duren deuterierung
|
CA2186900A1
(en)
|
1994-04-14 |
1995-10-26 |
Christopher Joseph Aquino |
Cck or gastrin modulating 5-heterocyclic-1,5-benzodiazepines
|
PE27497A1
(es)
|
1994-04-15 |
1997-08-07 |
Glaxo Inc |
Derivados de 1,5 benzodiazepina
|
EP0755394A1
(en)
|
1994-04-15 |
1997-01-29 |
Glaxo Wellcome Inc. |
A method of inducing cholecystokinin agonist activity using 1,4-benzodiazepine compounds
|
FR2723739B1
(fr)
|
1994-08-19 |
1997-02-14 |
Sanofi Sa |
Derives de glycinamide, procedes pour leur preparation et medicaments les contenant.
|
GB9420747D0
(en)
|
1994-10-14 |
1994-11-30 |
Glaxo Inc |
1,5 benzodiazepine derivatives
|
GB9420763D0
(en)
|
1994-10-14 |
1994-11-30 |
Glaxo Inc |
Acetamide derivatives
|
US5990077A
(en)
|
1995-04-14 |
1999-11-23 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 and its therapeutic use
|
EP0906338B1
(en)
|
1996-04-12 |
2002-11-06 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 analogs
|
FR2763337B1
(fr)
|
1997-05-13 |
1999-08-20 |
Sanofi Sa |
Nouveaux derives du triazole, un procede pour leur preparation et compositions pharmaceutiques les contenant
|
CO4970713A1
(es)
|
1997-09-19 |
2000-11-07 |
Sanofi Synthelabo |
Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
|
AR022044A1
(es)
|
1999-05-06 |
2002-09-04 |
Glaxo Group Ltd |
Derivados de 1,5-benzodiazepina
|
US20040019091A1
(en)
|
2000-10-26 |
2004-01-29 |
Eric Bignon |
Triazole derivatives and pharmaceutical compositions comprising them
|
HUP0004741A2
(hu)
|
2000-11-28 |
2002-12-28 |
Sanofi-Synthelabo |
Kémiai eljárás tiazolszármazékok előállítására és új intermedier
|
US7112567B2
(en)
|
2001-02-16 |
2006-09-26 |
Conjuchem Inc. |
Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
|
EP1369698A1
(en)
|
2002-06-07 |
2003-12-10 |
Bayer Ag |
Diagnostics and therapeutics for diseases associated with somatostatin receptor 5 (SSTR5)
|
DE60332475D1
(de)
*
|
2002-10-30 |
2010-06-17 |
Vertex Pharma |
Zusammensetzungen verwendbar für die hemmung von rock und anderen kinasen
|
WO2005035793A2
(en)
|
2003-10-09 |
2005-04-21 |
Decode Genetics Ehf. |
Cckar markers and haplotypes associated with extreme weight conditions
|
WO2005051890A1
(en)
|
2003-11-19 |
2005-06-09 |
Smithkline Beecham Corporation |
Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
|
US7517910B2
(en)
|
2004-03-30 |
2009-04-14 |
Takeda Pharmaceutical Company Limited |
Alkoxyphenylpropanoic acid derivatives
|
EA010888B1
(ru)
|
2004-05-25 |
2008-12-30 |
Пфайзер Продактс, Инк. |
Тетраазабензо[е]азуленовые производные и их аналоги
|
JP2007284350A
(ja)
|
2004-07-27 |
2007-11-01 |
Takeda Chem Ind Ltd |
糖尿病治療剤
|
EP1843766A1
(en)
|
2005-01-28 |
2007-10-17 |
Merck & Co., Inc. |
Antidiabetic bicyclic compounds
|
ATE440091T1
(de)
|
2005-01-31 |
2009-09-15 |
Merck & Co Inc |
Antidiabetische bicyclische verbindungen
|
US20060177438A1
(en)
|
2005-02-08 |
2006-08-10 |
New England Medical Center |
Methods of altering absorption of hydrophobic compounds
|
EP2295452A1
(en)
|
2005-05-04 |
2011-03-16 |
Zealand Pharma A/S |
Glucagon-like-peptide-2 (GLP-2) analogues
|
KR100962732B1
(ko)
|
2005-06-02 |
2010-06-09 |
에프. 호프만-라 로슈 아게 |
피페리딘-4-일-아마이드 유도체 및 sst 수용체 아형 5길항제로서 그의 용도
|
US20070212355A1
(en)
|
2005-10-24 |
2007-09-13 |
Baker Audrey E |
GLP-2 Mimetibodies, Polypeptides, Compositions, Methods and Uses
|
US20090313709A1
(en)
|
2006-01-31 |
2009-12-17 |
Yoshihiko Kaisho |
Genetically Modified Animal and Use Thereof
|
NZ571412A
(en)
|
2006-04-14 |
2010-07-30 |
Merck & Co Inc |
Substituted imidazole 4-carboximides as cholecystokinin-1 receptor modulators
|
JP2009533445A
(ja)
|
2006-04-14 |
2009-09-17 |
メルク エンド カムパニー インコーポレーテッド |
コレシストキニン−1受容体モジュレータとしての置換イミダゾール4−カルボキサミド
|
TW200815377A
(en)
|
2006-04-24 |
2008-04-01 |
Astellas Pharma Inc |
Oxadiazolidinedione compound
|
EP2021327B1
(en)
|
2006-05-15 |
2012-04-04 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
US7812121B2
(en)
|
2006-08-31 |
2010-10-12 |
Baker Audrey E |
GLP-2 mimetibodies, polypeptides, compositions, methods and uses
|
US8338394B2
(en)
|
2006-10-12 |
2012-12-25 |
Case Western Reserve University |
Methods for treating metabolic diseases
|
WO2008054674A2
(en)
|
2006-10-31 |
2008-05-08 |
Merck & Co., Inc. |
Antidiabetic bicyclic compounds
|
EP2079467B1
(en)
|
2006-10-31 |
2015-11-18 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
CA2669806C
(en)
|
2006-11-08 |
2018-10-02 |
Zealand Pharma A/S |
Selective glucagon-like-peptide-2 (glp-2) analogues
|
US7750048B2
(en)
|
2006-11-15 |
2010-07-06 |
Janssen Pharmaceutica Nv |
GPR40 agonists
|
WO2008067222A1
(en)
|
2006-11-28 |
2008-06-05 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5
|
US20090035306A1
(en)
|
2006-11-29 |
2009-02-05 |
Kalypsys, Inc. |
Quinazolinone modulators of tgr5
|
CN101679476B
(zh)
|
2007-01-19 |
2014-05-07 |
英特塞普特医药品公司 |
23取代的胆汁酸作为tgr5调节剂及其使用方法
|
AU2008209472A1
(en)
|
2007-01-26 |
2008-07-31 |
Merck Sharp & Dohme Corp. |
Substituted aminopyrimidines as cholecystokinin-1 receptor modulators
|
US20080221161A1
(en)
|
2007-02-09 |
2008-09-11 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
WO2009026241A1
(en)
|
2007-08-23 |
2009-02-26 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5
|
JP2010539152A
(ja)
|
2007-09-10 |
2010-12-16 |
プロシディオン・リミテッド |
代謝障害の治療のための化合物
|
EP2197873B1
(en)
|
2007-09-20 |
2014-07-16 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
JP5427784B2
(ja)
|
2007-09-21 |
2014-02-26 |
サノフイ |
(カルボキシルアルキレン−フェニル)−フェニル−オキサルアミド、その製造方法、及び薬剤としてのその使用
|
AU2008303975B2
(en)
|
2007-09-21 |
2013-05-16 |
Sanofi |
(Cyclopropyl-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
|
ES2401233T3
(es)
|
2007-10-17 |
2013-04-18 |
Universidad de Córdoba |
Isoformas del receptor tipo 5 de somatostatina humana producidas por tratamiento alternativo y pares de oligonucleótidos para la detección de las mismas por PCR
|
JP2011016722A
(ja)
|
2007-10-23 |
2011-01-27 |
Astellas Pharma Inc |
チアゾリジンジオン化合物
|
CA2703106C
(en)
|
2007-10-24 |
2015-12-01 |
Astellas Pharma Inc. |
Azolecarboxamide derivatives as trka inhibitors
|
TW200932219A
(en)
|
2007-10-24 |
2009-08-01 |
Astellas Pharma Inc |
Oxadiazolidinedione compound
|
CL2008003153A1
(es)
|
2007-10-26 |
2009-07-24 |
Japan Tobacco Inc |
Compuestos espiro condensados, agonistas de gpr40: composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en la preparacion de medicamentos para el tratamiento de la diabetes, hiperglicemia, alteracion de tolerancia a la glucosa en ayuna, entre otras.
|
EP2215068B1
(en)
|
2007-10-29 |
2012-06-13 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
WO2009106565A1
(en)
*
|
2008-02-27 |
2009-09-03 |
Biovitrum Ab (Publ) |
Agonists of gpr119
|
JP5665160B2
(ja)
|
2008-03-26 |
2015-02-04 |
パナソニックIpマネジメント株式会社 |
発光装置および照明器具
|
BRPI0911118A2
(pt)
|
2008-04-07 |
2015-10-06 |
Irm Llc |
composto e compisições como moduladores de atividade de gpr119
|
GB0812648D0
(en)
*
|
2008-07-10 |
2008-08-20 |
Prosidion Ltd |
Compounds
|
WO2010014739A2
(en)
|
2008-07-29 |
2010-02-04 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5
|
EA020310B1
(ru)
|
2008-07-30 |
2014-10-30 |
Интерсепт Фармасьютикалз, Инк. |
Модуляторы рецептора tgr5 и их применение
|
WO2010016846A1
(en)
|
2008-08-08 |
2010-02-11 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
WO2010042145A1
(en)
|
2008-09-19 |
2010-04-15 |
Nektar Therapeutics |
Polymer conjugates of glp-2-like peptides
|
EP2358200A4
(en)
|
2008-11-17 |
2012-05-16 |
Merck Sharp & Dohme |
BICYCLIC AMINES SUBSTITUTED FOR THE TREATMENT OF DIABETES
|
PL2376519T3
(pl)
|
2008-11-19 |
2014-04-30 |
Intercept Pharmaceuticals Inc |
Modulatory TGR5 i sposoby ich zastosowania
|
EP3150620B1
(en)
|
2008-11-19 |
2020-01-08 |
Intercept Pharmaceuticals, Inc. |
Tgr5 modulators and methods of use thereof
|
WO2010067233A1
(en)
|
2008-12-08 |
2010-06-17 |
Pfizer Inc. |
1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
|
US20110312967A1
(en)
|
2009-01-23 |
2011-12-22 |
Schering Corporation |
Bridged and fused antidiabetic compounds
|
CA2749663A1
(en)
|
2009-01-23 |
2010-07-29 |
Hubert B. Josien |
Pentafluorosulpholane-containing antidiabetic compounds
|
JP2012515781A
(ja)
|
2009-01-23 |
2012-07-12 |
シェーリング コーポレイション |
架橋および縮合複素環式抗糖尿病化合物
|
EP2393810A1
(en)
|
2009-02-05 |
2011-12-14 |
Schering Corporation |
Phthalazine-containing antidiabetic compounds
|
JP2012517479A
(ja)
|
2009-02-12 |
2012-08-02 |
エグゼリクシス, インコーポレイテッド |
糖尿病および肥満の処置においてtgr5アゴニストとして使用するためのトリアゾールおよびイミダゾール誘導体
|
EP2399914A4
(en)
|
2009-02-18 |
2012-08-29 |
Takeda Pharmaceutical |
FUSED HETEROCYCLIC RING CONNECTION
|
CN102421739A
(zh)
|
2009-04-22 |
2012-04-18 |
安斯泰来制药株式会社 |
羧酸化合物
|
JP2012136438A
(ja)
|
2009-04-22 |
2012-07-19 |
Astellas Pharma Inc |
テトラゾール化合物
|
EP2440541A1
(en)
|
2009-06-09 |
2012-04-18 |
Takeda Pharmaceutical Company Limited |
Novel fused cyclic compound and use thereof
|
AR078522A1
(es)
|
2009-10-15 |
2011-11-16 |
Lilly Co Eli |
Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
|
EP2314616A1
(en)
|
2009-10-23 |
2011-04-27 |
Ferring B.V. |
Peptidic GLP-2 agonists
|
EP2495238A4
(en)
|
2009-10-30 |
2013-04-24 |
Mochida Pharm Co Ltd |
NEW 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE
|
AR078948A1
(es)
|
2009-11-30 |
2011-12-14 |
Lilly Co Eli |
Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
|
TW201120027A
(en)
|
2009-12-11 |
2011-06-16 |
Exelixis Inc |
TGR5 agonists
|
MX2012007474A
(es)
|
2009-12-25 |
2012-08-01 |
Mochida Pharm Co Ltd |
Derivados de 3-hidroxi-5-arilisotiazol novedosos.
|
EP2571356A4
(en)
|
2010-05-18 |
2013-11-20 |
Merck Sharp & Dohme |
SPIROISOXAZOLIN COMPOUNDS AS SSTR5 ANTAGONISTS
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
AU2011281134B2
(en)
|
2010-07-23 |
2015-05-14 |
Connexios Life Sciences Pvt. Ltd. |
Agonists of GPR40
|
EP2605658B1
(en)
|
2010-08-18 |
2016-03-23 |
Merck Sharp & Dohme Corp. |
Spiroxazolidinone compounds
|
CN103314010B
(zh)
|
2010-08-30 |
2015-03-04 |
Nps制药股份有限公司 |
h[Gly2]GLP-2的固相合成
|
WO2012046869A1
(ja)
|
2010-10-08 |
2012-04-12 |
持田製薬株式会社 |
環状アミド誘導体
|
WO2012070554A1
(ja)
|
2010-11-22 |
2012-05-31 |
国立大学法人京都大学 |
ペプチド
|
UY33758A
(es)
|
2010-12-01 |
2012-06-29 |
Boehringer Ingelheim Int |
Acidos indaniloxidihidrobenzofuranilaceticos
|
WO2012082947A1
(en)
|
2010-12-16 |
2012-06-21 |
Irm Llc |
Compounds and compositions as tgr5 agonists
|
BR112013020634A2
(pt)
|
2011-02-17 |
2016-10-25 |
Takeda Pharmaceutical |
método para produzir uma forma opticamente ativa de um composto, sal, complexo de rutênio, composto, e, cristal
|
CA2831334A1
(en)
*
|
2011-04-08 |
2012-10-11 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
|
AU2012240102C1
(en)
|
2011-04-08 |
2016-09-08 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
|
MX2013012520A
(es)
|
2011-04-27 |
2014-02-03 |
Mochida Pharm Co Ltd |
Derivado novedoso de 1-oxido de 3-hidroxi isotiazol.
|
EP2702042A1
(en)
|
2011-04-28 |
2014-03-05 |
Bristol-Myers Squibb Company |
Novel bicyclic nitrogen containing heteroaryl tgr5 receptor modulators
|
WO2012173917A1
(en)
*
|
2011-06-16 |
2012-12-20 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
|
WO2013054338A1
(en)
|
2011-07-06 |
2013-04-18 |
Cadila Healthcare Limited |
2-thio-imidazole derivatives as tgr5 modulators
|
TWI537262B
(zh)
|
2011-08-17 |
2016-06-11 |
美國禮來大藥廠 |
供治療糖尿病使用之新穎1,2,3,4-四氫喹啉衍生物
|
ES2687651T3
(es)
|
2011-09-12 |
2018-10-26 |
Amunix Operating Inc. |
Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos
|
WO2013057743A1
(en)
|
2011-10-21 |
2013-04-25 |
Connexios Life Sciences Pvt. Ltd |
Process for the preparation of an aryl oxime and salts thereof
|
US9018224B2
(en)
*
|
2011-11-15 |
2015-04-28 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds useful as GPR119 agonists
|
WO2013096771A1
(en)
|
2011-12-21 |
2013-06-27 |
Ardelyx, Inc. |
Non-systemic tgr5 agonists
|
CN103429581B
(zh)
|
2012-01-12 |
2015-08-26 |
江苏恒瑞医药股份有限公司 |
多环类衍生物、其制备方法及其在医药上的应用
|
GB2498976A
(en)
*
|
2012-02-01 |
2013-08-07 |
Prosidion Ltd |
GPR119 agonists useful in the treatment of type II diabetes
|
JP6095580B2
(ja)
|
2012-02-13 |
2017-03-15 |
武田薬品工業株式会社 |
芳香環化合物
|
EP2816032A4
(en)
|
2012-02-13 |
2015-09-30 |
Takeda Pharmaceutical |
AROMATIC CORE COMPOUND
|
AU2013227266A1
(en)
|
2012-02-28 |
2014-10-02 |
Piramal Enterprises Limited |
Phenyl alkanoic acid derivatives as GPR agonists
|
US8642585B2
(en)
|
2012-03-26 |
2014-02-04 |
Boehringer Ingelheim International Gmbh |
Indanyloxydihydrobenzofuranylacetic acids
|
WO2013154163A1
(ja)
|
2012-04-11 |
2013-10-17 |
持田製薬株式会社 |
新規5-アリール-1,2-チアジナン誘導体
|
US8809376B2
(en)
|
2012-04-30 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
Indanyloxydihydrobenzofuranylacetic acids
|
CA2872315A1
(en)
|
2012-05-03 |
2013-11-07 |
Zealand Pharma A/S |
Glucagon-like-peptide-2 (glp-2) analogues
|
US8633182B2
(en)
|
2012-05-30 |
2014-01-21 |
Boehringer Ingelheim International Gmbh |
Indanyloxyphenylcyclopropanecarboxylic acids
|
WO2014019186A1
(en)
|
2012-08-02 |
2014-02-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
US20150274664A1
(en)
*
|
2012-09-26 |
2015-10-01 |
Marck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
|
BR112015009395A2
(pt)
|
2012-10-26 |
2017-07-04 |
Intercept Pharmaceuticals Inc |
processo para preparação de derivados do ácido biliar
|
TWI692469B
(zh)
|
2012-11-09 |
2020-05-01 |
南韓商Lg化學股份有限公司 |
Gpr40受體促效劑,製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物
|
NZ708501A
(en)
|
2012-11-28 |
2019-03-29 |
Intercept Pharmaceuticals Inc |
Treatment of pulmonary disease
|
WO2014082918A1
(en)
|
2012-11-28 |
2014-06-05 |
Boehringer Ingelheim International Gmbh |
New indanyloxydihydrobenzofuranylacetic acids
|
JP6283862B2
(ja)
|
2012-12-07 |
2018-02-28 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規インダニルオキシジヒドロベンゾフラニル酢酸
|
WO2014100021A1
(en)
|
2012-12-17 |
2014-06-26 |
Exelixis, Inc. |
Tgr5 agonists: imidazole and triazole compounds containing a quaternary nitrogen
|
WO2014100025A1
(en)
|
2012-12-17 |
2014-06-26 |
Exelixis, Inc. |
Tgr5 agonists having an imidazole or triazole core with subtituent having a quaternary nitrogen
|
WO2014096440A2
(en)
|
2012-12-21 |
2014-06-26 |
Novozymes Biopharma Dk A/S |
Composition
|
EP2953681B1
(en)
|
2013-02-06 |
2017-03-15 |
Boehringer Ingelheim International GmbH |
New indanyloxydihydrobenzofuranylacetic acids
|
CN104994848A
(zh)
|
2013-02-22 |
2015-10-21 |
默沙东公司 |
抗糖尿病二环化合物
|
CN104059039B
(zh)
|
2013-03-22 |
2017-03-15 |
正大天晴药业集团股份有限公司 |
具有gpr40受体功能调节作用的稠环化合物
|
CN104109115B
(zh)
|
2013-04-16 |
2016-11-23 |
中国科学院上海药物研究所 |
一种含氮杂环链接的苯丙酸类化合物、其药物组合物、制备方法和用途
|
AR096041A1
(es)
|
2013-04-17 |
2015-12-02 |
Piramal Entpr Ltd |
Derivados de ácido carboxílico alquilo sustituidos como agonistas rpg
|
CN104870429B
(zh)
|
2013-05-22 |
2017-05-03 |
四川海思科制药有限公司 |
苯并呋喃衍生物、其制备方法及其在医药上的应用
|
MX2015017035A
(es)
|
2013-06-13 |
2016-04-25 |
Fast Forward Pharmaceuticals B V |
Inhibidor de la señalizacion de cd40 y un compuesto adicional, en donde el compuesto adicional es un acido labil, un derivado de acido labil, un agonista del receptor tgr5, un agonista del fxr o una combinacion de los mismos, para el tratamiento de inflamacion cronica, y la prevencion de cancer gastrointestinal o fibrosis.
|
CN104507921B
(zh)
|
2013-07-02 |
2017-02-22 |
四川海思科制药有限公司 |
苯并环丁烯类衍生物、其制备方法及其在医药上的应用
|
CN105143181B
(zh)
|
2013-07-26 |
2017-12-26 |
四川海思科制药有限公司 |
三元并环羧酸类衍生物、其制备方法及其在医药上的应用
|
BR112016002213A2
(pt)
|
2013-07-31 |
2017-08-29 |
Amgen Inc |
Construtos do fator 15 de diferenciação de crescimento (gdf-15)
|
ES2672992T3
(es)
|
2013-08-09 |
2018-06-19 |
Takeda Pharmaceutical Company Limited |
Compuesto aromático
|
CN104418801B
(zh)
|
2013-08-19 |
2016-10-05 |
上海润诺生物科技有限公司 |
苯并哌啶环与苯并吗啉环类化合物、其制法及医药应用
|
US20160200734A1
(en)
|
2013-08-23 |
2016-07-14 |
Xinshan Kang |
Carboxylic acid compounds in treatment of diabetes mellitus
|
WO2015028960A1
(en)
|
2013-08-28 |
2015-03-05 |
Piramal Enterprises Limited |
Substituted heterocyclic derivatives as gpr agonists and uses thereof
|
CN105246875A
(zh)
|
2013-09-03 |
2016-01-13 |
四川海思科制药有限公司 |
茚满衍生物及其制备方法和在医药上的应用
|
WO2015044073A1
(en)
|
2013-09-26 |
2015-04-02 |
Boehringer Ingelheim International Gmbh |
Process and intermediates for preparing indanyloxydihydrobenzofuranyl acetic acid derivatives as gpr40 agonists
|
JO3442B1
(ar)
|
2013-10-07 |
2019-10-20 |
Takeda Pharmaceuticals Co |
مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
WO2015062486A1
(en)
|
2013-10-31 |
2015-05-07 |
Sunshine Lake Pharma Co., Ltd. |
Biphenyl compounds and uses thereof
|
US10011609B2
(en)
|
2013-11-14 |
2018-07-03 |
Cadila Healthcare Limited |
Heterocyclic compounds
|
US10519115B2
(en)
|
2013-11-15 |
2019-12-31 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
EP3074375B1
(en)
|
2013-11-28 |
2018-04-04 |
Boehringer Ingelheim International GmbH |
New indanyloxyphenylcyclopropanecarboxylic acids
|
EP3076959B1
(en)
|
2013-12-04 |
2018-07-04 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
TW201609722A
(zh)
|
2013-12-13 |
2016-03-16 |
美國禮來大藥廠 |
新穎三唑并吡啶化合物
|
WO2015089809A1
(en)
|
2013-12-19 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Antidiabetic substituted heteroaryl compounds
|
AU2015204916B2
(en)
|
2014-01-10 |
2017-02-23 |
Eli Lilly And Company |
Isopropyl triazolo pyridine compounds
|
BR112016013874A2
(pt)
|
2014-01-10 |
2017-08-08 |
Lilly Co Eli |
Fenil-triazolo-piridina, seus usos, seus processo de produção e seus intermediários, e composição farmacêutica
|
WO2015119899A1
(en)
|
2014-02-06 |
2015-08-13 |
Merck Sharp & Dohme Corp. |
Antidiabetic compounds
|
WO2015160772A1
(en)
|
2014-04-15 |
2015-10-22 |
Janssen Pharmaceutica Nv |
Tetrahydro-benzoimidazolyl modulators of tgr5
|
WO2015176267A1
(en)
|
2014-05-22 |
2015-11-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
WO2015183794A1
(en)
|
2014-05-27 |
2015-12-03 |
City Of Hope |
Tgr5 agonist complexes for treating diabetes and cancer
|
SI3626725T1
(sl)
|
2014-05-29 |
2023-04-28 |
Bar Pharmaceuticals S.R.L. |
Derivati holana za uporabo pri zdravljenju in/ali preprečevanju bolezni, posredovanih s FXR in TGR5/GPBAR1
|
WO2015198199A1
(en)
|
2014-06-23 |
2015-12-30 |
Novartis Ag |
Hsa-gdf-15 fusion polypeptide and use thereof.
|
EP3164538A1
(en)
|
2014-07-02 |
2017-05-10 |
Arçelik Anonim Sirketi |
Built-in household appliance unpowered control and status indication device
|
WO2016019587A1
(en)
|
2014-08-08 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
[7, 6]-fused bicyclic antidiabetic compounds
|
EP3177285B1
(en)
|
2014-08-08 |
2020-09-23 |
Merck Sharp & Dohme Corp. |
[5,6]-fused bicyclic antidiabetic compounds
|
WO2016022742A1
(en)
|
2014-08-08 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
WO2016022448A1
(en)
|
2014-08-08 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
WO2016032120A1
(ko)
|
2014-08-27 |
2016-03-03 |
씨제이헬스케어 주식회사 |
신규한 아미노-페닐-설포닐-아세테이트 유도체 및 이의 용도
|
WO2016054208A1
(en)
|
2014-10-03 |
2016-04-07 |
Mayo Foundation For Medical Education And Research |
Targeting tgr5 to treat disease
|
TW201629033A
(zh)
|
2014-10-08 |
2016-08-16 |
健生藥品公司 |
作為治療第二型糖尿病之gpr40促效劑的經取代苯并噻吩基衍生物
|
KR101726819B1
(ko)
*
|
2014-10-27 |
2017-04-13 |
동아에스티 주식회사 |
Gpr119 작용 활성을 갖는 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
|
US20180280480A1
(en)
|
2014-10-31 |
2018-10-04 |
Gubra Aps |
Compositions and peptides having dual glp-1r and glp-2r agonist activity
|
MX2017005935A
(es)
|
2014-11-06 |
2018-01-11 |
Enanta Pharm Inc |
Análogos de ácido biliar como agonistas fxr/tgr5 y métodos de uso de los mismos.
|
US11578097B2
(en)
|
2014-11-26 |
2023-02-14 |
Enanta Pharmaceuticals, Inc. |
Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
|
CA2975257A1
(en)
|
2015-02-11 |
2016-08-18 |
Enanta Pharmaceuticals, Inc. |
Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
|
CN107427527B
(zh)
|
2015-03-31 |
2021-01-26 |
英安塔制药有限公司 |
作为fxr/tgr5激动剂的胆汁酸衍生物及其使用方法
|
TW201712012A
(zh)
|
2015-06-16 |
2017-04-01 |
美國禮來大藥廠 |
2-側氧基-1,3,8-三氮雜螺[4.5]癸-3-基羧酸衍生物
|
MX2017016611A
(es)
|
2015-06-19 |
2018-05-15 |
Intercept Pharmaceuticals Inc |
Moduladores de tgr5 y metodos de uso de los mismos.
|
JP6772133B2
(ja)
|
2015-07-02 |
2020-10-21 |
サントリーホールディングス株式会社 |
Glp−2分泌促進用組成物
|
US20170008928A1
(en)
|
2015-07-06 |
2017-01-12 |
Novo Nordisk A/S |
Novel peptides and peptide derivatives and uses thereof
|
JP6816107B2
(ja)
|
2015-08-07 |
2021-01-20 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
インダニルアミノピリジルシクロプロパンカルボン酸、医薬組成物及びこれらの使用
|
EP3331896A4
(en)
|
2015-08-07 |
2019-08-14 |
Intercept Pharmaceuticals, Inc. |
PROCESSES FOR PREPARING BILIARY ACIDS AND THEIR DERIVATIVES
|
WO2017027310A1
(en)
|
2015-08-12 |
2017-02-16 |
Janssen Pharmaceutica Nv |
Gpr40 agonists for the treatment of type ii diabetes
|
US9920040B2
(en)
|
2015-08-12 |
2018-03-20 |
Janssen Pharmaceutica Nv |
GPR40 agonists for the treatment of type II diabetes
|
WO2017027312A1
(en)
|
2015-08-12 |
2017-02-16 |
Janssen Pharmaceutica Nv |
Gpr40 agonists for the treatment of type ii diabetes
|
JP2018526405A
(ja)
|
2015-09-09 |
2018-09-13 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
[{[2,3−ジヒドロ−1H−インデン−1−イル]アミノ}−2H,3H−フロ[3,2−b]ピリジン−3−イル]酢酸、それらの医薬組成物および使用
|
KR20180052756A
(ko)
|
2015-09-24 |
2018-05-18 |
인터셉트 파마슈티컬즈, 인크. |
담즙산 유도체 제조를 위한 방법 및 중간체
|
KR20180067699A
(ko)
|
2015-11-06 |
2018-06-20 |
인터셉트 파마슈티컬즈, 인크. |
오베티콜산 및 이의 유도체의 제조 방법
|
TWI773657B
(zh)
|
2015-12-18 |
2022-08-11 |
美商亞德利克斯公司 |
作爲非全身tgr5促效劑之經取代之4-苯基吡啶化合物
|
WO2017147159A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
|
US10323061B2
(en)
|
2016-02-23 |
2019-06-18 |
Enanta Pharmaceuticals, Inc. |
Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof
|
US10323060B2
(en)
|
2016-02-23 |
2019-06-18 |
Enanta Pharmaceuticals, Inc. |
Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
|
WO2017147742A1
(en)
|
2016-02-29 |
2017-09-08 |
Eli Lilly And Company |
Gfral receptor therapies
|
US10676458B2
(en)
|
2016-03-29 |
2020-06-09 |
Merch Sharp & Dohne Corp. Rahway |
Antidiabetic bicyclic compounds
|
US10106553B2
(en)
|
2016-04-11 |
2018-10-23 |
Janssen Pharmaceutica Nv |
Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes
|
CN109071452A
(zh)
|
2016-04-13 |
2018-12-21 |
英特塞普特医药品公司 |
治疗癌症的方法
|
US11236055B2
(en)
|
2016-07-01 |
2022-02-01 |
Venenum Biodesign, LLC |
Non-systemic TGR5 agonists
|
WO2018005794A2
(en)
|
2016-07-01 |
2018-01-04 |
Venenum Biodesign Llc |
Novel non-systemic tgr5 agonists
|
WO2018009778A1
(en)
|
2016-07-07 |
2018-01-11 |
Baylor College Of Medicine |
Combination of glp-1 and glp-2 for treating or preventing metabolic diseases, disorders and syndromes
|
JP2019529481A
(ja)
|
2016-09-30 |
2019-10-17 |
インターセプト ファーマシューティカルズ, インコーポレイテッド |
胆汁酸誘導体の結晶形態
|
KR20190059312A
(ko)
|
2016-10-12 |
2019-05-30 |
얀센 바이오테크 인코포레이티드 |
Gdf15-유사 생물학적 활성의 조절제에 대한 스크리닝 방법
|
US10988433B2
(en)
|
2016-10-25 |
2021-04-27 |
Janssen Pharmaceutica Nv |
Cyclohexyl GPR40 agonists for the treatment of type II diabetes
|
JP7050797B2
(ja)
|
2016-10-25 |
2022-04-08 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物および使用
|
EP3544958B1
(en)
|
2016-11-28 |
2021-03-24 |
Boehringer Ingelheim International GmbH |
Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
US11072602B2
(en)
|
2016-12-06 |
2021-07-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
CN110099922A
(zh)
|
2016-12-09 |
2019-08-06 |
西兰制药公司 |
Glp-1/glp-2双重激动剂
|
WO2018104558A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
WO2018104559A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Glp-1/glp-2 dual agonists
|
WO2018103868A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
BR112019010624A2
(pt)
|
2016-12-09 |
2019-10-22 |
Zealand Pharma As |
agonistas duplos de glp-1/glp-2 acilados e composição
|
KR102007633B1
(ko)
|
2016-12-15 |
2019-08-06 |
일동제약(주) |
신규 페닐 프로피온 산 유도체 및 이의 용도
|
US10968232B2
(en)
|
2016-12-20 |
2021-04-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic spirochroman compounds
|
JP7050792B2
(ja)
|
2017-01-26 |
2022-04-08 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ベンジルオキシピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用
|
US10793530B2
(en)
|
2017-01-26 |
2020-10-06 |
Boehringer Ingelheim International Gmbh |
Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
EP3573953A1
(en)
|
2017-01-26 |
2019-12-04 |
Boehringer Ingelheim International GmbH |
Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
US10919859B2
(en)
|
2017-01-26 |
2021-02-16 |
Boehringer Ingelheim International Gmbh |
Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
WO2018138026A1
(en)
|
2017-01-26 |
2018-08-02 |
Boehringer Ingelheim International Gmbh |
Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
WO2018142363A1
(en)
|
2017-02-06 |
2018-08-09 |
Orbicular Pharmaceutical Technologies Private Limited |
Ready to use compositions of glp-2 analogues through self-administrable devices
|
CN110300755B
(zh)
|
2017-02-08 |
2022-10-04 |
勃林格殷格翰国际有限公司 |
茚满基氨基氮杂二氢苯并呋喃乙酸、用于治疗糖尿病的药物组合物
|
GB201704714D0
(en)
|
2017-03-24 |
2017-05-10 |
Caldan Therapeutics Ltd |
Pharmaceutical compounds
|
CN110719903A
(zh)
|
2017-03-31 |
2020-01-21 |
武田药品工业株式会社 |
芳族环化合物
|
AR111199A1
(es)
|
2017-03-31 |
2019-06-12 |
Takeda Pharmaceuticals Co |
Compuesto aromático agonista de gpr40
|
CN107162921B
(zh)
|
2017-05-27 |
2019-12-13 |
中国药科大学 |
一类苯氧乙酸衍生物、其制备方法及其作为药物的用途
|
WO2018222701A1
(en)
|
2017-05-30 |
2018-12-06 |
Intercept Pharmaceuticals, Inc. |
Treatment of renal diseases with a bile acid derivative
|
WO2018226724A1
(en)
|
2017-06-05 |
2018-12-13 |
Intercept Pharmaceuticals, Inc. |
Treatment and prevention of diabetic eye diseases with a bile acid derivatives
|
TWI791539B
(zh)
|
2017-06-16 |
2023-02-11 |
丹麥商西蘭製藥公司 |
用於投予類升糖素胜肽-2(glp-2)類似物的給藥方案
|
IL271343B2
(en)
|
2017-06-23 |
2023-12-01 |
Intercept Pharmaceuticals Inc |
Methods and intermediates for the preparation of bile acid derivatives
|
EP3672621A4
(en)
|
2017-08-22 |
2021-11-24 |
Shire-NPS Pharmaceuticals, Inc. |
GLP-2 FUSION POLYPEPTIDES AND USES IN THE TREATMENT AND PREVENTION OF GASTROINTESTINAL DISORDERS
|
WO2019086559A1
(fr)
|
2017-10-31 |
2019-05-09 |
Adocia |
Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
CN111629745A
(zh)
|
2017-11-06 |
2020-09-04 |
夏尔-Nps医药品有限公司 |
用于在手术前、期间或之后投与的glp-2类似物和肽体(peptibodies)
|
EP3709995A4
(en)
|
2017-11-16 |
2021-04-14 |
Merck Sharp & Dohme Corp. |
BICYCLIC ANTIDIABETIC COMPOUNDS
|
DK3737470T5
(da)
|
2018-01-08 |
2024-05-27 |
Celon Pharma Sa |
3-phenyl-4-hexynsyrederivater som gpr40-agonister
|
US20220152164A1
(en)
|
2019-03-22 |
2022-05-19 |
Kallyope, Inc. |
Gpcr combination therapies
|
EP3976576A4
(en)
|
2019-05-29 |
2023-06-28 |
Kallyope, Inc. |
Gpr40 agonists
|
JP2022552655A
(ja)
|
2019-10-07 |
2022-12-19 |
キャリーオペ,インク. |
Gpr119アゴニスト
|
US20230113609A1
(en)
|
2019-12-03 |
2023-04-13 |
Kallyope, Inc. |
Sstr5 antagonists
|
IL295825A
(en)
|
2020-02-28 |
2022-10-01 |
Kallyope Inc |
gpr40 agonists
|
EP4110760A4
(en)
|
2020-02-28 |
2024-09-18 |
Kallyope Inc |
GPR40 AGONISTS
|